Cargando…

Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo

Tumors lack a well-regulated vascular supply of O(2) and often fail to balance O(2) supply and demand. Net O(2) tension within many tumors may not only depend on O(2) delivery but also depend strongly on O(2) demand. Thus, tumor O(2) consumption rates may influence tumor hypoxia up to true anoxia. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammon, Seth T., Pisaneschi, Federica, Bandi, Madhavi L., Smith, Melinda G., Sun, Yuting, Rao, Yi, Muller, Florian, Wong, Franklin, De Groot, John, Ackroyd, Jeffrey, Mawlawi, Osama, Davies, Michael A., Vashisht Gopal, Y.N., Di Francesco, M. Emilia, Marszalek, Joseph R., Dewhirst, Mark, Piwnica-Worms, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952969/
https://www.ncbi.nlm.nih.gov/pubmed/31766580
http://dx.doi.org/10.3390/cells8121487
_version_ 1783486542859206656
author Gammon, Seth T.
Pisaneschi, Federica
Bandi, Madhavi L.
Smith, Melinda G.
Sun, Yuting
Rao, Yi
Muller, Florian
Wong, Franklin
De Groot, John
Ackroyd, Jeffrey
Mawlawi, Osama
Davies, Michael A.
Vashisht Gopal, Y.N.
Di Francesco, M. Emilia
Marszalek, Joseph R.
Dewhirst, Mark
Piwnica-Worms, David
author_facet Gammon, Seth T.
Pisaneschi, Federica
Bandi, Madhavi L.
Smith, Melinda G.
Sun, Yuting
Rao, Yi
Muller, Florian
Wong, Franklin
De Groot, John
Ackroyd, Jeffrey
Mawlawi, Osama
Davies, Michael A.
Vashisht Gopal, Y.N.
Di Francesco, M. Emilia
Marszalek, Joseph R.
Dewhirst, Mark
Piwnica-Worms, David
author_sort Gammon, Seth T.
collection PubMed
description Tumors lack a well-regulated vascular supply of O(2) and often fail to balance O(2) supply and demand. Net O(2) tension within many tumors may not only depend on O(2) delivery but also depend strongly on O(2) demand. Thus, tumor O(2) consumption rates may influence tumor hypoxia up to true anoxia. Recent reports have shown that many human tumors in vivo depend primarily on oxidative phosphorylation (OxPhos), not glycolysis, for energy generation, providing a driver for consumptive hypoxia and an exploitable vulnerability. In this regard, IACS-010759 is a novel high affinity inhibitor of OxPhos targeting mitochondrial complex-I that has recently completed a Phase-I clinical trial in leukemia. However, in solid tumors, the effective translation of OxPhos inhibitors requires methods to monitor pharmacodynamics in vivo. Herein, (18)F-fluoroazomycin arabinoside ([(18)F]FAZA), a 2-nitroimidazole-based hypoxia PET imaging agent, was combined with a rigorous test-retest imaging method for non-invasive quantification of the reversal of consumptive hypoxia in vivo as a mechanism-specific pharmacodynamic (PD) biomarker of target engagement for IACS-010759. Neither cell death nor loss of perfusion could account for the IACS-010759-induced decrease in [(18)F]FAZA retention. Notably, in an OxPhos-reliant melanoma tumor, a titration curve using [(18)F]FAZA PET retention in vivo yielded an IC(50) for IACS-010759 (1.4 mg/kg) equivalent to analysis ex vivo. Pilot [(18)F]FAZA PET scans of a patient with grade IV glioblastoma yielded highly reproducible, high-contrast images of hypoxia in vivo as validated by CA-IX and GLUT-1 IHC ex vivo. Thus, [(18)F]FAZA PET imaging provided direct evidence for the presence of consumptive hypoxia in vivo, the capacity for targeted reversal of consumptive hypoxia through the inhibition of OxPhos, and a highly-coupled mechanism-specific PD biomarker ready for translation.
format Online
Article
Text
id pubmed-6952969
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69529692020-01-23 Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo Gammon, Seth T. Pisaneschi, Federica Bandi, Madhavi L. Smith, Melinda G. Sun, Yuting Rao, Yi Muller, Florian Wong, Franklin De Groot, John Ackroyd, Jeffrey Mawlawi, Osama Davies, Michael A. Vashisht Gopal, Y.N. Di Francesco, M. Emilia Marszalek, Joseph R. Dewhirst, Mark Piwnica-Worms, David Cells Article Tumors lack a well-regulated vascular supply of O(2) and often fail to balance O(2) supply and demand. Net O(2) tension within many tumors may not only depend on O(2) delivery but also depend strongly on O(2) demand. Thus, tumor O(2) consumption rates may influence tumor hypoxia up to true anoxia. Recent reports have shown that many human tumors in vivo depend primarily on oxidative phosphorylation (OxPhos), not glycolysis, for energy generation, providing a driver for consumptive hypoxia and an exploitable vulnerability. In this regard, IACS-010759 is a novel high affinity inhibitor of OxPhos targeting mitochondrial complex-I that has recently completed a Phase-I clinical trial in leukemia. However, in solid tumors, the effective translation of OxPhos inhibitors requires methods to monitor pharmacodynamics in vivo. Herein, (18)F-fluoroazomycin arabinoside ([(18)F]FAZA), a 2-nitroimidazole-based hypoxia PET imaging agent, was combined with a rigorous test-retest imaging method for non-invasive quantification of the reversal of consumptive hypoxia in vivo as a mechanism-specific pharmacodynamic (PD) biomarker of target engagement for IACS-010759. Neither cell death nor loss of perfusion could account for the IACS-010759-induced decrease in [(18)F]FAZA retention. Notably, in an OxPhos-reliant melanoma tumor, a titration curve using [(18)F]FAZA PET retention in vivo yielded an IC(50) for IACS-010759 (1.4 mg/kg) equivalent to analysis ex vivo. Pilot [(18)F]FAZA PET scans of a patient with grade IV glioblastoma yielded highly reproducible, high-contrast images of hypoxia in vivo as validated by CA-IX and GLUT-1 IHC ex vivo. Thus, [(18)F]FAZA PET imaging provided direct evidence for the presence of consumptive hypoxia in vivo, the capacity for targeted reversal of consumptive hypoxia through the inhibition of OxPhos, and a highly-coupled mechanism-specific PD biomarker ready for translation. MDPI 2019-11-21 /pmc/articles/PMC6952969/ /pubmed/31766580 http://dx.doi.org/10.3390/cells8121487 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gammon, Seth T.
Pisaneschi, Federica
Bandi, Madhavi L.
Smith, Melinda G.
Sun, Yuting
Rao, Yi
Muller, Florian
Wong, Franklin
De Groot, John
Ackroyd, Jeffrey
Mawlawi, Osama
Davies, Michael A.
Vashisht Gopal, Y.N.
Di Francesco, M. Emilia
Marszalek, Joseph R.
Dewhirst, Mark
Piwnica-Worms, David
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
title Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
title_full Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
title_fullStr Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
title_full_unstemmed Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
title_short Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [(18)F]FAZA PET In Vivo
title_sort mechanism-specific pharmacodynamics of a novel complex-i inhibitor quantified by imaging reversal of consumptive hypoxia with [(18)f]faza pet in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952969/
https://www.ncbi.nlm.nih.gov/pubmed/31766580
http://dx.doi.org/10.3390/cells8121487
work_keys_str_mv AT gammonsetht mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT pisaneschifederica mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT bandimadhavil mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT smithmelindag mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT sunyuting mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT raoyi mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT mullerflorian mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT wongfranklin mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT degrootjohn mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT ackroydjeffrey mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT mawlawiosama mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT daviesmichaela mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT vashishtgopalyn mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT difrancescomemilia mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT marszalekjosephr mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT dewhirstmark mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo
AT piwnicawormsdavid mechanismspecificpharmacodynamicsofanovelcomplexiinhibitorquantifiedbyimagingreversalofconsumptivehypoxiawith18ffazapetinvivo